Key Highlights

  • Total Revenue for the September quarter reached USD 127.7 million, compared with USD 110.3 million in 2025, while product revenue of USD 125.5 million grew 19%, figures released November 3, 2026.
  • Sales of IBSRELA totaled USD 96.3 million, rising 23% on the year, and XPHOZAH added USD 29.2 million, a 7% gain, based on the company release for the quarter ended September 30, 2026.
  • Operating income was USD 4.0 million and the net loss USD 0.7 million after USD 15.1 million of share-based compensation, with USD 285.3 million in cash and short-term investments.
  • Published market data placed the shares near USD 3.14, up 3.47%, on about 2.8 million shares of volume; the snapshot date is unconfirmed and the move is modest.

Third-Quarter Sales Expand as Profit Stays Thin

Ardelyx (NASDAQ:ARDX) announced its third-quarter 2026 numbers on November 3, 2026, showing total revenue of USD 127.7 million compared with USD 110.3 million in the same period of 2025. The company develops and sells medicines for gastrointestinal and kidney-related disorders, anchored by IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for lowering phosphorus in dialysis patients. Operating Income slid to USD 4.0 million from USD 4.7 million, so operating profit lagged sales growth, and the gap between those two rates is the figure to track. The quarter closed with a USD 0.7 million net loss, or USD 0.00 per share, compared with a USD 1.0 million loss in the third quarter of 2025.

IBSRELA Momentum, XPHOZAH Lag and Reaffirmed Targets

IBSRELA accounts for most revenue after reaching USD 96.3 million, while XPHOZAH grew more slowly, to USD 29.2 million, so their trajectories matter most to the top line. Full-year 2026 guidance was reaffirmed at USD 350 million to USD 370 million for IBSRELA and USD 110 million to USD 120 million for XPHOZAH, with operating expenses expected below USD 500 million. Enrollment in the Phase 3 ACCEL trial for chronic idiopathic constipation finished early, and topline results are expected in the second half of 2027. A new US Patent covering commercial formulations of both drugs is set to issue on November 10, 2026, according to the release.

Thin-Trading Risk and the Unverified Screen Move

At about USD 3.14 on the screened quote, Ardelyx (NASDAQ:ARDX) sits below the USD 5 level that defines a penny stock, despite its commercial product line. A Penny Stock can swing on a handful of trades, spreads can widen, and a 3.47% quoted gain may vanish quickly, so the move should not be read as a trend. Cash and short-term investments of USD 285.3 million support operations, yet the small loss shows profitability is not yet established. Share-based compensation of USD 15.1 million adds dilution pressure to weigh. Volume near 2.8 million shares comes from published market data whose date could not be verified.

Where Things Stand

Partly. Ardelyx (NASDAQ:ARDX) grew product revenue 19% and reaffirmed guidance, which supports the Business story. Against that, the quarter ended with a small net loss, XPHOZAH rose only 7%, and the 3.47% screen gain is too small and undated to signal momentum. The next markers are the patent issuance on November 10, 2026, progress toward the full-year ranges and the ACCEL data in the second half of 2027. Investors should also weigh how much of the revenue gain depends on one product line.